Adalimumab biosimilar utilization account for more than 80% of the drug category, as AbbVie’s Humira revenues dry up. Although the numbers are hard to come by, it seems apparent that adalimumab biosimilar sales have pounded the reference product Humira into submission through the second quarter of 2026. AbbVie announced Humira net revenues of only $425,000,000 … Continue reading US Humira Sales Overwhelmed by Biosimilar Competition
Copy and paste this URL into your WordPress site to embed
US Humira Sales Overwhelmed by Biosimilar Competition
Adalimumab biosimilar utilization account for more than 80% of the drug category, as AbbVie’s Humira revenues dry up. Although the numbers are hard to come by, it seems apparent that adalimumab biosimilar sales have pounded the reference product Humira into submission through the second quarter of 2026. AbbVie announced Humira net revenues of only $425,000,000 … Continue reading US Humira Sales Overwhelmed by Biosimilar Competition